Stock Research for TNXP

Current Price


Latest Update: 2018-03-19 16:00:00

$ 3.3500
$ 3.3300
$ 3.3500

Featured Broker: TradeStation

Get the due diligence for another stock.


TNXP Stock Chart & Research Data

The TNXP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TNXP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


TNXP Due diligence Resources & Stock Charts

The TNXP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View TNXP Detailed Price Forecast - CNN Money CNN View TNXP Detailed Summary - Google Finance
Yahoo View TNXP Detailed Summary - Yahoo! Finance Zacks View TNXP Stock Research & Analysis -

Stock Analysis

TradeIdeas View TNXP Trends & Analysis - Trade-Ideas Barrons View TNXP Major Holders - Barrons
NASDAQ View TNXP Call Transcripts - NASDAQ Seeking View TNXP Breaking News & Analysis - Seeking Alpha
Spotlight View TNXP Annual Report - OTC Report View TNXP OTC Short Report -
TradeKing View TNXP Fundamentals - TradeKing Charts View TNXP SEC Filings - Bar Chart
WSJ View Historical Prices for TNXP - The WSJ Morningstar View Performance/Total Return for TNXP - Morningstar
MarketWatch View the Analyst Estimates for TNXP - MarketWatch CNBC View the Earnings History for TNXP - CNBC
StockMarketWatch View the TNXP Earnings - StockMarketWatch MacroAxis View TNXP Buy or Sell Recommendations - MacroAxis
Bullish View the TNXP Bullish Patterns - American Bulls Short Pains View TNXP Short Pain Metrics -

Social Media Mentions

StockTwits View TNXP Stock Mentions - StockTwits PennyStocks View TNXP Stock Mentions - PennyStockTweets
Twitter View TNXP Stock Mentions - Twitter Invest Hub View TNXP Investment Forum News - Investor Hub
Yahoo View TNXP Stock Mentions - Yahoo! Message Board Seeking Alpha View TNXP Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for TNXP - Insider Cow View Insider Transactions for TNXP - Insider Cow
CNBC View TNXP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for TNXP - OTC Markets
Yahoo View Insider Transactions for TNXP - Yahoo! Finance NASDAQ View Institutional Holdings for TNXP - NASDAQ

Stock Charts

FinViz View TNXP Stock Insight & Charts - StockCharts View TNXP Investment Charts -
BarChart View TNXP Stock Overview & Charts - BarChart Trading View View TNXP User Generated Charts - Trading View

Latest Financial News for TNXP

TNXP: Phase 3 Trial in PTSD Nearing 50% Enrollment; Interim Analysis in 3Q18
Posted on Monday March 19, 2018

In 2017, Tonix (TNXP) announced the first patient was enrolled in the Phase 3 HONOR study of TNX-102 SL 5.6 mg for the treatment of posttraumatic stress disorder (PTSD, NCT03062540). The HONOR trial is a 12-week, multicenter, randomized, double blind, placebo controlled, fixed dose study of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets) taken at bedtime. Approximately 550 subjects who have served in the military and meet a diagnosis of PTSD according to the Clinician-Administered PTSD Scale (CAPS-5) for DSM-5 are eligible to enroll.

Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
Posted on Tuesday March 13, 2018

NEW YORK, March 13, 2018-- Tonix Pharmaceuticals Holding Corp., announced today that it will present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium being held March 15-17, ...

Tonix reports 4Q loss
Posted on Monday March 12, 2018

The New York-based company said it had a loss of 71 cents per share. Losses, adjusted for non-recurring costs, were 67 cents per share. For the year, the company reported that its loss narrowed to $21.1 ...

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update
Posted on Monday March 12, 2018

Interim Analysis for Phase 3 HONOR study of Tonmya ® in Military-Related PTSD Expected in Third Quarter of 2018; Topline Results Expected in Fourth Quarter of 2018. NEW YORK, March 12, 2018-- Tonix Pharmaceuticals ...

Warning: DOMDocument::load(): StartTag: invalid element name in, line: 1 in /home/allsites/ on line 494

Warning: DOMDocument::load(): Extra content at the end of the document in, line: 1 in /home/allsites/ on line 494

Enter a stock symbol to view the stock details.